Bio waiver for lower strength (250mg) Mycophenolate mofetil tablet [Regulatives / Guidelines]

posted by Nidhiya J S – United Arab Emirates, 2019-11-05 06:14 (929 d 03:11 ago) – Posting: # 20749
Views: 3,287

(edited by Nidhiya J S on 2019-11-06 06:08)

Dear All,

Greetings!

Please, I would like to know that, with the In vitro comparative dissolution study report can we waive off BE In vivo study with in vitro comparative dissolution study for the lower strength for Mycophenolate mofetil tablet 250mg or do we require separate BE study for the lower strength.


And also I would like to know that whether similar approach can be taken for all the pro-drug where the metabolite of the drug is pharmacologically active.


Waiting for your valuable comments.

With Regards,

Nidhiya

Complete thread:

UA Flag
Activity
 Admin contact
22,091 posts in 4,630 threads, 1,566 registered users;
online 17 (0 registered, 17 guests [including 14 identified bots]).
Forum time: Sunday 10:26 CEST (Europe/Vienna)

Competence, like truth, beauty and contact lenses,
is in the eye of the beholder.    Laurence J. Peter

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5